NESACAINE (chloroprocaine hydrochloride) by Fresenius Kabi is clinical pharmacology chloroprocaine, like other local anesthetics, blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse and by reducing the rate of rise of the action potential. First approved in 1955.
Drug data last refreshed 23h ago · AI intelligence enriched 1w ago
NESACAINE (chloroprocaine hydrochloride) is a short-acting local anesthetic administered by injection that blocks nerve impulse generation and conduction for pain relief during surgical and dental procedures. It works by increasing the electrical excitation threshold in nerves and slowing action potential propagation. Patients undergoing procedures requiring rapid-onset, short-duration local anesthesia are the primary users.
As a 69-year-old product approaching loss of exclusivity with moderate competitive pressure, team size and growth investment are likely constrained.
CLINICAL PHARMACOLOGY Chloroprocaine, like other local anesthetics, blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse and by reducing the rate of rise of the…
Worked on NESACAINE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Observational Study on 2-chloroprocaine Hydrochloride 1%
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on NESACAINE offers exposure to lifecycle management, compliance, and operational excellence in a stable, mature injectable product rather than cutting-edge development or commercial expansion. The approaching LOE and low linked job count indicate limited hiring growth and suggest career focus on efficiency, risk mitigation, and portfolio protection.